Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Vali A. Papadimitrakopoulou, MD, and Fabrice Denis, MD, PhD, on Lung Cancer: Improving Survival With an App

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discuss findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006). To see Dr. Denis discuss this study in French, click here.

To see the French language version of this discussion, click here.

Bladder Cancer

Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1

Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advanced/metastatic disease (Abstract LBA4500).

Prostate Cancer

Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies

Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts 5001, 5003, 5023, and 5021).

Issues in Oncology

Lee S. Schwartzberg, MD, on Progress of the Institute for Clinical Immuno-Oncology

Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices.

Colorectal Cancer

Heinz-Josef Lenz, MD, and Marc Ychou, MD, on Treating mCRC With Initially Nonresectable Liver Metastases

Heinz-Josef Lenz, MD, of the University of Southern California, and Marc Ychou, MD, of the Centre Régional de Lutte Contre Le Cancer, discuss study findings on FOLFIRINOX combined with targeted therapy according to RAS status for colorectal cancer patients with initially nonresectable liver metastases (Abstract 3512).

Mar

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Vali A. Papadimitrakopoulou, MD, and Fabrice Denis, MD, PhD, on Lung Cancer: Improving Survival With an App

Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1

Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies

Lee S. Schwartzberg, MD, on Progress of the Institute for Clinical Immuno-Oncology

Heinz-Josef Lenz, MD, and Marc Ychou, MD, on Treating mCRC With Initially Nonresectable Liver Metastases

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden

2026 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

Prostate Cancer: Low Testosterone Levels May Be Associated With Increased Risk of Progression During Surveillance

Stanford Names Leader for Drug Development and Precision Oncology